Core Viewpoint - The article highlights the rising flu activity in southern China, with predictions of an earlier flu season this year compared to last, primarily driven by the different circulating strain, H3N2, which the public has lower immunity against [2][3]. Group 1: Flu Activity and Strain Information - The current flu season is characterized by the predominance of the H3N2 strain, contrasting with last year's H1N1 strain, indicating a need for heightened awareness due to lower public immunity [3]. - Clinical symptoms of H3N2 include high fever, cough, sore throat, body aches, fatigue, and headache, which are similar to other flu strains [3]. Group 2: Vaccination Recommendations - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with the recommended vaccination period being from September to November to ensure immunity before peak season [5]. - Annual vaccination is necessary due to the rapid mutation of flu viruses, which may differ from year to year, thus requiring updated protection [6]. - High-risk groups, including children under 5, the elderly over 65, pregnant women, and those with chronic health conditions, are advised to receive vaccinations promptly [10]. Group 3: Vaccine Types and Administration - The available flu vaccines in China include inactivated (split) vaccines (trivalent/quadrivalent), inactivated (subunit) vaccines (trivalent/quadrivalent), and live attenuated vaccines (trivalent, nasal spray) [8]. - The difference between trivalent and quadrivalent vaccines lies in the number of virus strains they protect against, with quadrivalent covering an additional B strain, although the practical effectiveness may not differ significantly [8].

Market Overview - The Chinese medicine sector experienced a decline of 0.62% on October 20, with WoHua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Te Yi Pharmaceutical (002728) with a closing price of 9.34, up 5.30% and a trading volume of 439,400 shares [1] - Zhongsheng Pharmaceutical (002317) closed at 18.20, up 4.30% with a trading volume of 656,100 shares [1] - Panlong Pharmaceutical (002864) closed at 30.76, up 2.84% with a trading volume of 36,600 shares [1] - Conversely, WoHua Pharmaceutical (002107) saw a significant decline of 5.26%, closing at 6.30 with a trading volume of 215,700 shares [2] - Other notable decliners included: - Pianzi Shou (600436) down 4.71% to 187.09 [2] - Zhendong Pharmaceutical (300158) down 2.97% to 6.85 [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 371 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2] - The net inflow from speculative funds was 117 million yuan [2] Individual Stock Capital Flow - Zhongsheng Pharmaceutical (002317) had a net inflow of 62.17 million yuan from institutional investors, but a net outflow of 74.45 million yuan from retail investors [3] - Te Yi Pharmaceutical (002728) saw a net inflow of 54.06 million yuan from institutional investors, with a net outflow of 40.37 million yuan from retail investors [3] - Yunnan Baiyao (000538) had a net inflow of 9.54 million yuan from institutional investors, but a net outflow of 36.07 million yuan from retail investors [3]

Core Viewpoint - On October 20, Te Yi Pharmaceutical experienced a 5.3% increase in stock price, reaching 9.34 CNY per share, with a trading volume of 145 million CNY and a turnover rate of 4.26%, resulting in a total market capitalization of 4.788 billion CNY [1] Company Overview - Te Yi Pharmaceutical Group Co., Ltd. is located in Taicheng, Guangdong Province, and was established on May 23, 2002, with its listing date on July 31, 2014 [1] - The company's main business involves the research, development, production, and sales of traditional Chinese medicine, chemical preparations, and chemical raw materials [1] - The revenue composition of the company is as follows: Traditional Chinese medicine 61.00%, chemical preparations 32.61%, chemical raw materials 5.77%, and chemical products and others 0.61% [1] Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under GF Fund holds a significant position in Te Yi Pharmaceutical [2] - GF Xinhe Mixed A (004750) held 246,200 shares in the second quarter, accounting for 0.21% of the fund's net value, ranking as the tenth largest heavy stock [2] - The estimated floating profit for today is approximately 115,700 CNY [2] - GF Xinhe Mixed A was established on January 16, 2018, with a latest scale of 171 million CNY, and has achieved a year-to-date return of 3.42% [2] - The fund manager, Wu Di, has a tenure of 5 years and 168 days, with a total asset scale of 77.42 billion CNY [2]

Group 1 - 2025 marks a significant year for the development of innovative drugs in China, with 43 innovative drugs approved in the first half, 40 of which are developed by domestic companies [1] - The National Medical Products Administration (NMPA) has approved a total of 210 innovative drugs and 269 innovative medical devices during the 14th Five-Year Plan period, indicating a trend of accelerated growth [1] - Continuous policy support from the government has provided a strong impetus for the development of innovative drugs, creating a transparent and stable policy environment [2][3] Group 2 - Companies like China Resources Sanjiu have adopted a "brand + innovation" dual-drive strategy, significantly increasing their focus on innovation in response to national policies and market demands [3] - China Resources Sanjiu reported obtaining 8 drug registration certificates and has 205 ongoing research projects, covering various fields including cardiovascular and oncology [3] - Other notable companies in the innovative drug sector include Teva Pharmaceutical, Tai Chi Group, and Yiling Pharmaceutical, all of which are enhancing their competitiveness through increased R&D investment and talent acquisition [4][5] Group 3 - The number of innovative traditional Chinese medicine (TCM) drugs is on the rise, with 5 TCM innovative drugs approved in the first half of 2025, reflecting a growing trend in this sector [5] - As of July 31, 2025, there are 147 TCM innovative drugs in clinical stages or above, a threefold increase compared to 2020, indicating a significant expansion in TCM innovation [5] - The Chinese innovative drug industry has made remarkable breakthroughs in quantity, quality, and technology over the past decade, entering a new development phase with promising future prospects [5]

Core Viewpoint - The company held an online investor reception day to address investor concerns regarding performance, marketing reforms, and R&D plans, emphasizing its commitment to enhancing company value and market communication [1] Group 1: Investor Relations Activity - The investor reception day took place on September 19, 2025, via the "Panorama Roadshow" website, with participation from various investors [1] - Key company representatives included Chairman and General Manager Xu Ronghuang, Financial Director and Vice General Manager Chen Xiliang, and Board Secretary Xu Zilan [1] Group 2: Financial Performance and Marketing Strategy - The company acknowledged that its stock price is influenced by various factors, including short-sellers, and is focused on enhancing market value through marketing reforms, channel optimization, brand building, and R&D innovation [1] - Sales expenses increased by 172 million yuan in the first half of 2025 for brand building, which temporarily pressured profits but improved brand recognition [1] - The core product, cough relief tablets, saw significant growth on e-commerce platforms, with a 260% increase on Alibaba and a 652% increase on JD.com [1] Group 3: Sales and Marketing Reforms - Sales in the second quarter were affected by seasonal fluctuations and marketing strategy adjustments, leading to a decrease in volume [1] - The company reported a sales expense of 69.08 million yuan in Q2 2025, up from 34.19 million yuan in the same period last year and 45.08 million yuan in 2023 [1] - The marketing organization has undergone structural upgrades, resulting in a net increase of over 100 frontline sales personnel [1] Group 4: R&D and Future Plans - The company is pursuing dual-track R&D in traditional Chinese medicine and chemical drugs, focusing on existing product development and innovative drug research [1] - There are currently no plans to engage in stablecoin or virtual currency business in Hong Kong [1] Group 5: Market Communication and Transparency - The company is actively communicating with investors and enhancing information disclosure transparency as part of its market value management initiatives [1]

Performance Overview - The company achieved a revenue of 491.14 million yuan in the first half of 2025, representing a year-on-year growth of 56.54% [12] - The net profit attributable to shareholders reached 38.01 million yuan, a significant increase of 1313.23% compared to the previous year [12][13] - Sales of the core product, "Te Yi" cough tablets, amounted to 331 million pieces, recovering to 61.29% of the sales volume from the same period in 2023 [11][14] Marketing and Brand Strategy - The company increased its marketing expenses to 172 million yuan in the first half of 2025, primarily for brand building [3][11] - Online sales channels have been expanded, with significant growth in e-commerce platforms: Alibaba saw a 260% increase, JD.com 652%, and Pinduoduo ranked among the top three bestsellers [4][11] - The marketing organization has been restructured, adding over 100 sales personnel to enhance operational efficiency [10][11] Future Growth Initiatives - The company plans to continue enhancing its channel layout, focusing on both online and offline sales, particularly in chain pharmacies [2][3] - There is an emphasis on strengthening the "1+N" product matrix, with a focus on core products like "Te Yi" cough tablets and potential growth products [3][11] - Ongoing investment in R&D and product development is aimed at supporting long-term growth, particularly in respiratory and traditional Chinese medicine sectors [8][10] Market Communication and Investor Relations - The management is committed to improving communication with the capital market through various channels, including performance briefings and investor interactions [3][14] - The company acknowledges the impact of macroeconomic factors on stock performance but remains focused on enhancing intrinsic value and shareholder returns [8][14]

股票代码：002728 股票简称：特一药业 公告编号：2025-059 特一药业集团股份有限公司 届时公司董事长、总经理许荣煌先生，董事、财务总监、副总经理陈习良先生，董 事会秘书许紫兰女士将在线就 2025 年半年度业绩、公司治理、发展战略、经营状况和 可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 特一药业集团股份有限公司 董事会 2025 年 9 月 17 日 关于参加广东辖区 2025 年投资者网上集体接待日活动的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，特一药业集团股份有限公司（以下简称"公司"） 将参加由广东证监局、广东上市公司协会联合举办的"向新提质 价值领航——2025 年 广东辖区投资者集体接待日暨辖区上市公司中报业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五） 15:30-17:00。 ...

Group 1 - The company, Te Yi Pharmaceutical, announced the convening of its sixth board meeting on August 21, 2025, to review the half-year report for 2025 [1] - For the first half of 2025, Te Yi Pharmaceutical's revenue composition was as follows: pharmaceutical industry accounted for 98.52%, pharmaceutical commerce for 0.87%, and chemical products and others for 0.61% [1] - As of the report date, Te Yi Pharmaceutical's market capitalization was 4.8 billion yuan [1]

Group 1 - The company, Teva Pharmaceutical Industries Ltd, stated that the number of shareholders at non-periodic reporting times is not mandatory information disclosure [1] - Shareholders wishing to inquire about the number of shareholders must provide written documentation proving their shareholding, including personal identification and valid shareholding certificates [1] - To ensure fairness in information disclosure and equal access to information for all investors, the company will disclose the number of shareholders at specific points in time in its periodic reports [1]

Investment Rating - The report assigns a "Buy" rating for the company, marking it as the first recommendation [6]. Core Insights - The marketing reform initiated in early 2024 has begun to reveal the market potential of the company's core product, the cough relief tablets, with sales recovering significantly [4]. - The company reported a substantial increase in revenue and net profit for the first half of 2025, with revenue reaching 491.14 million yuan, a year-on-year growth of 56.54%, and net profit of 38.01 million yuan, a remarkable increase of 1313.23% [3]. - The company aims to cultivate its cough relief tablets into a major traditional Chinese medicine product, leveraging its historical significance and established market position [5]. Summary by Sections Financial Performance - The company achieved a revenue of 491.14 million yuan in the first half of 2025, reflecting a 56.54% increase year-on-year [3]. - The net profit for the same period was 38.01 million yuan, showing a dramatic increase of 1313.23% compared to the previous year [3]. Marketing Strategy - The sales reform for the cough relief tablets involved transitioning from a distributor model to a mixed model of self-operated and distributor sales, which initially led to a decline in shipments but has now started to show positive results [4]. - In the first half of 2025, the sales volume of cough relief tablets reached 331 million pieces, recovering to 61.29% of the volume from the same period in 2023, indicating the effectiveness of the marketing reform [4]. Earnings Forecast - The company is projected to achieve revenues of 990 million yuan, 1.11 billion yuan, and 1.32 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding EPS of 0.22 yuan, 0.38 yuan, and 0.56 yuan [6][8]. - The current stock price corresponds to a PE ratio of 42.6, 24.7, and 16.8 for the years 2025, 2026, and 2027, respectively, suggesting a favorable outlook for rapid profit growth [6].